Filament Health Announces Private Placement Of Units And Convertible Debenture Units Of Up To $2,500,000
Financing driven by psychedelic investment fund Negev Capital and leading functional mushroom manufacturer Nammex
Filament Health Announces Annual General Meeting Voting Results
Vancouver, British Columbia, June 28, 2022 – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, is pleased to announce that shareholders overwhelmingly approved all proposed resolutions at its Annual General Meeting (”AGM”) of shareholders held virtually this morning. At the AGM, there were 28 holders of the common shares […]
Filament Health Announces Patient Dosing Through Health Canada Special Access Program
Vancouver, British Columbia, June 16, 2022 – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that a patient has been dosed with one of Filament’s drug candidates through the Health Canada Special Access Program (SAP). Filament is continuing the development of its drug candidates through clinical trials […]
Filament Health Cultivates 70th Psychedelic Mushroom Variety And Announces Annual General Meeting
Vancouver, British Columbia, June 10, 2022 – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has cultivated its 70th variety of psilocybin-containing mushrooms at its 3,500 square foot GMP-compliant facility in Metro Vancouver. Filament also announced the successful development of standardized, pharmaceutical-grade ayahuasca extract, designed […]
Filament Health and Jaguar Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications
Drug discovery collaboration will leverage the botanical drug development expertise of both companies
Filament Health is Issued Second Patent by United States Patent and Trademark Office and Reports Q1 Results
The patent describes the extraction and standardization of stable doses of psychedelic compounds The Company also reports first quarter 2022 financial results and operational highlights Vancouver, British Columbia, May 18, 2022 – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a second […]
Filament Health Announces Fourth Patent Issuance
The patent describes the extraction and standardization of stable doses of psychedelic compounds
Filament Health and Psyence Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products
The partnership leverages Psyence’s expertise in fungi cultivation and palliative care as well as Filament’s expertise in the manufacture of pharmaceutical grade drug candidates
Filament Health is Issued Patent by United States Patent and Trademark Office
The patent describes the extraction and standardization of stable doses of psychedelic compounds
Filament Health Announces Pre-IND Meeting With United States Food and Drug Administration
Vancouver, British Columbia, April 12, 2022 – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced it has held a pre-investigational new drug application (PIND) meeting with the United States Food and Drug Administration (FDA) Division of Psychiatry (The Division). During the course of the meeting, Filament and […]